Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient.
Hodgkin lymphoma is a curable disease in the vast majority of cases with a cure rate approaching 85 to 95% with initial therapy. However, some patients experience relapse and in patients with relapsed/refractory disease, prognosis remains poor and active agents are needed in this setting. Bendamustine is an alkylating agent with clinical activity against various lymphomas including follicular, mantle, diffuse large B cell lymphoma, and chronic lymphocytic leukemia; however, its activity in Hodgkin lymphoma is not yet well established. We report a case of a 55-year-old man with relapsed Hodgkin lymphoma that is heavily pretreated and was successfully treated with four cycles of single agent bendamustine (90 mg/m(2)) with complete response after two cycles and without any significant toxicity. These findings suggest that bendamustine is highly active in Hodgkin lymphoma.
Department of Hematology Oncology, Appalachian Regional Healthcare (ARH), Hazard, Kentucky, USA.
Raymond
R
Elsoueidi
Department of Pharmacy, Hazard ARH Regional Medical Center, Hazard, Kentucky, USA.
Alem
A
Mulat
Department of Pharmacy, Hazard ARH Regional Medical Center, Hazard, Kentucky, USA heshamourad@yahoo.com.
Hesham
H
Mourad
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction
D018906:Antineoplastic Agents, Alkylating; D000069461:Bendamustine Hydrochloride
Bendamustine; Hodgkin lymphoma; pretreated